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Abstract 
This study was conducted to investigate whether augmentation of macular pigment (MP) 
enhances visual performance (VP). 121 normal subjects were recruited. The active (A) group 
consumed 12mg of lutein (L) and 1 mg of zeaxanthin (Z) daily. MP optical density (MPOD) was 
assessed by customized heterochromatic flicker photometry. VP was assessed as best 
corrected visual acuity (BCVA), mesopic and photopic contrast sensitivity (CS), glare disability, 
photostress, and subjective visual function. Subjects were assessed at baseline; three; six; 12 
months (V1, V2, V3 and V4, respectively). Central MPOD increased significantly in the A group 
(P < 0.05) but not in the placebo group (P > 0.05). This statistically significant increase in MPOD 
in the A group was not, in general, associated with a corresponding improvement in VP (p > 
0.05, for all variables), with the exception of a statistically significant time/treatment effect in 
“daily tasks comparative analysis” (p = 0.03). At V4, we report statistically significant differences 
in mesopic CS at 20.7 cpd, mesopic CS at 1.5 cpd under high glare conditions, and light/dark 
adaptation comparative analysis between the lower and the upper MP tertile groups (p < 0.05) 
Further study into the relationship between MP and VP is warranted, with particular attention 
directed towards individuals with low MP and suboptimal VP. 
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Introduction 
The dietary carotenoids zeaxanthin (Z) and lutein (L) and L’s retinal isomer meso-zeaxanthin 
(meso-Z) are lipid-like molecules that accumulate at the macula, where they are collectively 
referred to as macular pigment (MP).(Bone et al. 1993)  An average western diet contains about 
1.3 to 3 mg/day of L and Z combined,(Nebeling et al. 1997a;Nebeling et al. 1997b) with 
significantly more L than Z (represented by an estimated ratio of 7: 1).  Approximately 78% of 
dietary L and Z is sourced from vegetables.(Sommerburg et al. 1998)  L is found in highest 
concentrations in dark green leafy vegetables, such as spinach, kale, and collard 
greens.(Sommerburg, Keunen, Bird, & van Kuijk 1998)  Z is the major carotenoid found in 
orange peppers, and oranges, with a high mole percentage of both L and Z being found in egg 
yolk,(Sommerburg, Keunen, Bird, & van Kuijk 1998) with comparable amounts of L and Z 
recently reported in corn and a variety of corn containing products (e.g. cornmeal and 
cereal).(Perry, Rasmussen, & Johnson 2009)   Possible dietary sources of meso-Z include 
shrimp, certain marine fish, and turtles, none of which are found in a typical western diet,(Maoka 
et al. 1986) however, it has recently been suggested that MZ may be present in some other, yet 
to be identified, foods.(Connolly et al. 2010) 
The macula is a specialized part of the retina, as it mediates central vision, provides 
sharpest visual acuity, and facilities best color discrimination.(Hirsch & Curcio 1989)  Age-
related macular degeneration (AMD) is a disease of the macula and results in the loss of central 
and color vision. AMD is the most common cause of blindness in the elderly population in the 
developed world.(Congdon et al. 2004) It is now understood that oxidative stress,(Beatty et al. 
2000;Winkler et al. 1999) exacerbated in part by cumulative short-wavelength visible light 
exposure,(Algvere, Marshall, & Seregard 2006;Fletcher et al. 2008) is important in the 
aetiopathogenesis of AMD. MP is a short-wavelength (blue) light filter(Bone, Landrum, & Cains 
1992) and a powerful antioxidant,(Khachik, Bernstein, & Garland 1997) and is therefore 
believed to protect against AMD.(Loane et al. 2008) This hypothesis, referred to as the 
“protective” hypothesis of MP, has been studied and reported on extensively.(Loane, Kelliher, 
Beatty, & Nolan 2008)  
Beyond its “protective” hypothesis, MP’s optical and anatomic properties have prompted 
the “optical” hypotheses of this pigment.  The “optical” hypotheses of MP have been previously 
discussed by Reading et al.(Reading & Weale 1974) and later by Nussbaum et al.,(Nussbaum, 
Pruett, & Delori 1981b) and include MP’s putative ability to enhance visual performance and/or 
comfort by attenuation of the effects of chromatic aberration and light scatter, via its short wave 
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light-filtering properties.(Walls & Judd 1933). This traditional description of the “optical 
hypothesis” does not account for additional mechanisms whereby MP may enhance visual 
performance, that are, perhaps, unrelated to the short wave filtration properties of MP. MP has 
been shown to exhibit dichroic properties (Hemenger 1982) which may facilitate the reduction of 
glare disability through preferential absorption of polarized light. Higher MPOD has also been 
observed to relate to a trend towards lower root-mean-square wavefront aberrations (in 
particular, higher order aberrations), thereby enhancing visual performance.(Kvansakul et al. 
2006)  
There is one additional, and important, mechanism, whereby MP may have a beneficial 
effect on visual performance and experience. The antioxidant properties of the MP carotenoids 
may attenuate or prevent the deleterious effects of free radical damage on the physiological 
functions of the photoreceptors and their axons. 
Many studies (to date mostly cross-sectional in design) have evaluated, and reported on 
the role of MP in visual performance, including: visual acuity; contrast sensitivity; glare disability; 
photostress recovery; critical flicker fusion frequency (CFF); color vision (amongst 
others).(Bartlett & Eperjesi 2008;Engles, Wooten, & Hammond 2007;Hammond, Jr. & Wooten 
2005;Kvansakul, Rodriguez-Carmona, Edgar, Barker, Kopcke, Schalch, & Barbur 
2006;Loughman et al. 2010a;Rodriguez-Carmona et al. 2006;Stringham & Hammond, Jr. 
2007;Stringham & Hammond 2008;Stringham, Fuld, & Wenzel 2004;Wooten & Hammond 2002) 
However, a placebo controlled, randomized, L-based supplementation trial was needed to 
investigate if augmentation of MPOD actually enhances visual performance and/or comfort. The 
Collaborative Optical Macular Pigment ASsessment Study (COMPASS), presented here, was 
designed specifically to answer this important research question. 
 
Methods 
Subjects and study sites 
COMPASS was conducted at Waterford Institute of Technology (WIT) and Dublin Institute of 
Technology (DIT), vision science laboratories, located in the southeast and east of the Republic 
of Ireland, respectively.  One hundred and twenty one healthy subjects volunteered to 
participate in this two-centered study, which was approved by the research ethics committees at 
both study sites.   Self-selected recruitment of subjects (WIT: n = 61 and DIT: n = 60) was 
facilitated by poster and newsletter advertisement, and also by word of mouth, in the respective 
local communities.  Informed consent was obtained from each volunteer, and the experimental 
procedures adhered to the tenets of the Declaration of Helsinki.  
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All subjects were aged between 18 to 41 years, in perfect general (self report) and ocular health 
(see below), and with visual acuity of at least 20/30 in the study eye. A typical study visit lasted 
approximately four hours. Subjects were assessed at baseline, three, six, and 12 months (V1, 
V2, V3 and V4, respectively).  All subjects recruited into the study were classed as naïve 
observers to the tests carried out (with the exception of the visual acuity test, with which all 
subjects were familiar). However, to optimize performance, and also to minimize any potential 
learning effects on performance, all subjects underwent a defined period of pre-test training.  
This training consisted of careful explanation of the nature of each test, pictorial and/or video 
demonstration of the test requirements and procedure, and was followed by a defined session 
of pre-test practice.  
 
Study design and formulation 
COMPASS is a registered trial on the ISRCTN database (number 35481392), and is a 
randomized placebo-controlled clinical trial of oral supplementation with a formulation containing 
the macular carotenoids (L and Z) and co-antioxidants versus placebo. The tablets used in the 
current study were hard film coated tablets. The daily dose of two tablets for the active (A) group 
consisted of 12 mg L, 1 mg Z (provided as ester), 120 mg vitamin C, 17.6 mg vitamin E, 10 mg 
zinc and 40 µg selenium. The placebo (P) consisted of cellulose, lactose and magnesium 
stearate, and was manufactured to be identical to the A preparation in terms of size and colour.  
The study tablets for the A and P groups were packaged into identical blister packs which 
contained the subjects’ anonymized unique identification number and COMPASS study label 
information. Subjects were instructed to consume the daily dose of two tablets with a meal.  
 
Compliance was assessed by tablet counting at each study visit, and encouraged by frequent 
reminder telephone calls and text messages by the study COMPASS research team. 
Compliance was also assessed at the end of the study by quantifying L and Z concentrations in 
serum, at each study visit, using high performance liquid chromatography (HPLC).    
 
Demographic, medical history, lifestyle and vision case history questionnaires  
The following details were  recorded, for each volunteer, on a purpose designed case report 
form: demographics; general health status; smoking habits (never, current or past); alcohol 
consumption (average unit weekly intake); exercise (minutes per week); body mass index (BMI, 
Kg/m2); blood pressure; ethnicity; marital status; education; occupation.  
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          A vision case history was also performed, and details reported included: time since last 
eye examination; spectacles or contact lens use; history of ocular treatment or surgery; history 
of occlusion therapy or visual training in childhood; family history of eye disease; current 
problems with vision; asthenopia associated with computer use; history of headaches.  
 
Spectacle refraction, visual acuity, and ocular dominance 
Each subject underwent precise spectacle refraction by an experienced optometrist to 
determine refractive error and best corrected visual acuity (BCVA) for each eye. A computer 
generated LogMAR test chart (Test Chart 2000 Pro; Thomson Software Solutions) was used to 
determine BCVA at a viewing distance of 4 meters, using a Sloan ETDRS letterset. BCVA was 
determined as the average of 3 measurements, with letter and line changes facilitated by the 
software pseudo-randomization feature.  Best corrected visual acuity was recorded using a 
letter-scoring visual acuity rating, with 20/20 visual acuity assigned a value of 100. Best 
corrected visual acuity was scored relative to this value, with each letter correctly identified 
assigned a nominal value of one, so that, for example, a BCVA of 20/20+1 equated to a score of 
101, and 20/20-1 to 99. The study eye was selected on the basis of ocular dominance, 
determined using the Miles Test (Roth, Lora, & Heilman 2002)with the dominant eye chosen as 
the study eye, except in cases of observed equidominance, in which case the right eye was 
selected.  All subsequent tests were conducted with the subject’s optimal subjective refraction in 
place. 
 
Glare disability 
Glare disability is a term used to describe the degradation of visual performance typically 
caused by loss of retinal image contrast. Glare disability is often caused, for example, by 
surface light reflections, or bright light sources such as car headlights, and typically is a 
consequence of increased forward light scatter within the eye.  Glare disability was assessed 
using a Functional Acuity Contrast Test (FACT),(Hitchcock, Dick, & Krieg 2004;Terzi et al. 2005) 
displayed using the Functional Vision Analyzer (Hohberger et al. 2007) (Stereo Optical Co., Inc., 
Chicago, IL), which is a desktop device that allows the measurement of contrast sensitivity, and 
includes a customized internal glare source for assessing the impact of glare on this measure of 
visual performance. The test comprised linear, vertically oriented, sine wave gratings presented 
at five different spatial frequencies including 1.5, 3, 6, 12 and 18 cycles per degree (cpd). Nine 
circular patches were presented at each spatial frequency, the contrast of each patch 
decreasing by 0.15 log units from the previous.  Gratings were tilted -15°, 0° or +15° with 
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respect to the vertical, to keep them within the orientation bandwidth of the visual channel. The 
background was tapered into a grey field in order to keep retinal illumination constant and avoid 
ghost imaging. Baseline contrast sensitivity was determined on the basis of the lowest contrast 
compatible with accurate determination of patch orientation across all five spatial frequencies for 
mesopic [3 candelas per meter squared (cdm-2)] instrument background conditions, initially in 
the absence of a glare source.  Subjects were asked to identify grating orientation, starting with 
the patch at highest contrast, and continuing until identification was no longer possible due to 
reducing contrast. Subjects were instructed not to guess, but to respond “don’t know” if patch 
orientation could not be correctly identified. As this procedure represented a non-standard 
psychophysical method of threshold detection, each subject was required to re-identify the 
orientation of certain gratings in a pseudo-random fashion in order to confirm the validity of the 
subject responses at each spatial frequency. Glare disability was assessed using a radial glare 
source consisting of 12 white LEDs arranged circumferentially in an oval pattern surrounding the 
grating charts (ranging from 4.5° to 6° from central fixation). These LEDs have a color 
temperature of 6500K, and the spectral emission profile demonstrated a single large peak at 
453nm (close to MP peak absorption), where the spectral irradiance was approximately double 
that of the peak emissions in the flatter emission spectrum across mid to long wavelengths. Two 
customized intensity settings were used to determine the effect of different levels of glare on 
contrast sensitivity. Glare source settings were set at a medium intensity of 42 Lux and a higher 
intensity of 84 Lux. All correct responses were entered into the Eyeview software provided, and 
contrast sensitivity scores for no glare, medium and high glare conditions were determined for 
the respective spatial frequencies. 
 
Visual Function in Normals questionnaire   
A 30-part, non-validated, Visual Function in Normals questionnaire (VFNq30) was designed 
specifically for the study (JL). The design was based loosely on a previously validated visual 
activities questionnaire,(Sloane et al. 1992) but adapted to suit a normal, young and healthy 
population sample. This questionnaire allowed the subject to quantify their visual performance 
using three separate metrics: situational analysis (SA) which required the subject to rate their 
visual performance in specified daily life situations; comparative analysis (CA) which required 
the subject to compare their perceived visual performance to that of their peers/family/friends; 
subject satisfaction score (SSS) which required the subject to provide an overall estimate of 
their perceived quality of vision.  Each of the three metrics above was computed to give a 
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performance score for five different functional aspects of their vision: acuity/spatial vision; glare 
disability; light/dark adaptation; daily visual tasks; color discrimination. 
 
Contrast sensitivity function 
A Dell Dimension 9200 computer and a Metropsis Visual Stimulus Generation device (VSG 
(ViSaGe S/N: 81020197), Cambridge Research Systems Ltd, Cambridge, U.K.) were used to 
generate and control the stimuli. The VSG provided 14-bit output resolution per phosphor. The 
stimuli were displayed on a 19’’ ViewSonic professional series p227f colour CRT flat screen 
monitor with a frame rate of 119.98Hz. The resolution of the monitor was set to 1024 x 769 
pixels. Non-linearities in the screen luminance output were eliminated by gamma correction 
prior to testing using a photometer system (Opti-Cal; Minolta, Japan). The Metropsis software 
calculated the inverse curves required to correct for the monitor’s non-linearities.  
The Metropsis contrast sensitivity system generated luminance modulated sine gratings 
(Gabor patches). The orientation of the stimuli was vertical. The Gabor patches were presented 
on the CRT monitor and subtended a visual angle of 4.2 degrees. The mean luminance was 
used as the background luminance. The Gabor had a two-dimensional spatial Gaussian 
envelope and was radially symmetrical with equal standard deviations, x and y.  
Contrast sensitivity functions were determined under both mesopic and photopic 
conditions. Each subject was seated at a fixed viewing distance of 1.5m from the CRT monitor. 
Natural pupils were used throughout the experiment. The non-dominant eye was occluded. 
Testing was carried out in a light free (other than CRT background mesopic and photopic light) 
environment. The subject was dark adapted for 5 minutes and a five-minute training session 
was given prior to testing under mesopic conditions. Subject responses were recorded using a 
handheld responder (CR6, Cambridge Research Systems Ltd, Cambridge, U.K), which 
communicated with the VSG device via an infra red link. A four alternate forced choice testing 
system was used, with 4 possible target locations. The stimuli were randomly presented at 2 
degrees spatial offset from the central cross target. The subject indicated the location of the 
target in relation to the fixation cross using the appropriate button on the responder box. The 
subject’s contrast sensitivity was determined for 5 different spatial frequencies (1.0, 4.1, 7.5, 
11.8 and 20.7 cpd) under both mesopic and photopic conditions, all at a mean luminance of 
3cdm-2 (mesopic) and 100cdm-2 (photopic).  
 A linear staircase method was used to determine the contrast threshold. The first Gabor 
at a particular location was presented at an initial contrast level where it was anticipated that the 
observer would be able to detect the Gabor patch for that particular spatial frequency (initial 
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contrast settings were informed by a brief pilot study involving 5 young healthy subjects).  
Subsequently, the contrast of the Gabor patch was varied using an adaptive staircase 
procedure, which was computer controlled and depended upon the subject’s responses. The 
stimulus contrast was reduced in steps of 0.3 log units until the subject did not detect the Gabor 
patch (first reversal). The contrast was subsequently increased by 0.15-log unit steps until the 
subject saw the Gabor patch and responded correctly (second reversal). The Metropsis 
software calculated the contrast threshold for each location and spatial frequency by taking the 
mid-point between the mean for peaks and troughs for 12 reversal points. The standard 
deviation was calculated by taking the deviations of the peak reversals from their peak means 
and using the average square of these deviations to calculate a peak variance. This method 
was repeated for the troughs. The square root of both variances were then calculated and 
averaged to provide the threshold standard deviation.   
For each subject, the Metropsis software plotted the inverse of the contrast threshold 
against the range of spatial frequencies tested to provide a contrast sensitivity function under 
both mesopic and photopic conditions.  
 
Photostress recovery  
Photostress recovery time (PRT) was calculated using a macular automated photostress (MAP) 
test. (Dhalla et al. 2007;Dhalla & Fantin 2005) MAP is a novel photostress method for the 
evaluation of macular function using the Humphrey® field analyzer (Model 745i Carl Zeiss 
Meditec Inc. Dublin, CA, USA).  The foveal threshold feature of the field analyzer was used to 
establish baseline foveal sensitivity as the average of three consecutive foveal sensitivity 
measurements recorded in decibels (dB), with each dB representing a 0.1log unit sensitivity 
variation.  
Following baseline foveal sensitivity calculation, the subject was exposed to a 
photostress stimulus, which consisted of a 5-second exposure to a 300-watt, 230 volt tungsten 
lamp head from a viewing distance of one meter. The spectral irradiance in the wavelength 
range, 300 nm to 800 nm, was measured using a  Bentham DMc 150 double monochromator 
scanning spectroradiometer. The input optic consisted of a very high precision cosine response 
diffuser (f2 error < 1%) and the measurements were performed in 1 nm intervals. Calibration 
was carried out with reference to a quartz-halogen lamp traceable to the UK National Physical 
Laboratory. The illuminance at 1 meter was obtained by using the photopic weighting function.  
Immediately post-photostress, a continuous and timed cycle of foveal sensitivity 
measurements were conducted and recorded for each subject. The reduction in foveal 
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sensitivity from baseline, along with the time taken to recover to baseline foveal sensitivity, was 
recorded.  
 
Macular pigment optical density 
We used the Macular Densitometer™, a device developed and originally described by Wooten 
et al.,(Wooten et al. 1999) to measure MPOD, including its spatial profile across the retina (i.e. 
0.25, 0.5, 1.0, 1.75 and 3 degrees of retinal eccentricity).  The Macular Densitometer™ uses 
heterochromatic flicker photometry (HFP) to obtain a valid measure of MPOD at a given retinal 
location.(Hammond, Jr., Wooten, & Smollon 2005) This method has recently been refined and is 
now referred to as customized HFP or cHFP. For a detailed description of this protocol please 
see recent publications by our research group and others.(Loane et al. 2007;Nolan et al. 
2009;Stringham et al. 2008) One subject (cwit2553) was excluded from analysis due to inability 
to use the Densitometer to obtain reliable MPOD data. 
 
Fundus photography 
Fundus photographs were obtained in both eyes using a NIDEK non-mydriatic fundus camera 
(AFC-230). Fundus photographs were assessed by an expert eyecare professional to exclude 
fundoscopically evident retinal pathology.  
 
Statistical analysis  
The statistical software package SPSS (version 17) and the statistical programming language R 
were used for analysis.  It was determined at the outset of the study that a minimum sample 
size of 91 subjects was required in order to detect an effect size (correlation between two 
continuous variables) of 0.4 at the 5% level of significance with high power. However, 121 
subjects were recruited into the study in order to allow for dropouts and for other possible 
analyses, in particular repeated measures analysis. 
 
All continuous variables at baseline exhibited a typical normal distribution.  Mean ± SDs are 
presented in the text and tables.  Comparisons of A and P groups at baseline were conducted 
using independent samples t-tests and chi-square analysis, as appropriate.  
 
We conducted repeated measures analysis of MPOD at each retinal eccentricity measured, for 
each of four study visits using a general linear model approach, with treatment (i.e. A and P) 
and smoking habits (non-smoker, past and current cigarette smoker) as between-subjects 
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factors.  Where appropriate we used the Greenhouse-Geisser correction for violation of 
sphericity. We used the 5% level of significance throughout our analysis, without adjustment for 
multiple testing. 
 
Four visual performance (VP) variables (assessed subjectively by questionnaire) in this study 
were recorded as percentage change of V4 score compared to V1 score. Repeated measures 
analysis would not have been appropriate for these, and instead they were analysed using a 
general linear model with V4 percentage change as the dependent variable and fixed between-
subjects factors treatment and smoking habits as explanatory variables.  
 
Results 
Baseline findings 
The demographic, lifestyle, dietary and serum carotenoid concentrations, MPOD, and vision 
data of  all 121 subjects recruited into the study, and divided by study arm (i.e. A or P group), 
are summarized in Table 1. As seen from this table, there was no significant difference between 
the A and P groups with respect to lifestyle, vision, and MP data, with the exception of a 
statistically significant difference between these groups for smoking habits (p = 0.046). Smoking 
status was therefore considered as a potential confounding variable and was controlled for 
throughout repeated measures analysis. The COMPASS baseline findings have already been 
published in a separate manuscript in this journal and, therefore, are not discussed in the 
current manuscript.(Loughman, Akkali, Beatty, Scanlon, Davison, O'Dwyer, Cantwell, Major, 
Stack, & Nolan 2010a) 
 
Longitudinal findings   
Supplement Compliance  
Seventy six subjects returned tablets, and (based on the number of tablets returned) 94.7% of 
these subjects averaged at least one tablet per day.  The average number of tablets per day 
was 1.57 in the A group and 1.65 in the P group, a difference that is not statistically significant 
(ANOVA, p=0.32). In comparing change in MPOD and VP variables between A and P groups, 
therefore, it was not deemed necessary to control for differences in compliance in the two 
groups. 
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Macular Pigment Optical Density 
We conducted repeated measures ANOVA of MPOD, for all retinal eccentricities measured (i.e. 
at 0.25º, 0.5º, 1.0 º, 1.75 º, and 3º), over time (i.e. over the study period [at V1, V2, V3, and V4, 
respectively]), using a general linear model approach, with two between-subjects factors: 
treatment (A, P) and smoking habits (never, past, current smoker).  As seen in Fig. 1, there was 
a trend (in the A group) towards an increase in MPOD at all eccentricities measured, but this 
increase was only statistically significant (at the 5% level) at the more central measured 
eccentricities (i.e. at 0.25º, 0.5º and 1.75º).  
 
Figure 2 (obtained from R statistical program) shows MPOD variation at 0.25º for 20 
consecutive individual subjects from each of the A and P groups. The graphs are arranged so 
that those with lowest MP are in the bottom row, and only subjects who presented for all 4 visits 
are displayed. 
 
Serum concentrations of lutein and zeaxanthin 
We conducted repeated measures analysis of serum concentrations of L and Z over time (i.e. 
over the study period) including all study visits (V1, V2, V3 and V4), using a general linear 
model approach, with treatment and cigarette smoking as between-subjects factors.  As seen in 
Fig. 3, there was a statistically significant time/treatment interaction effect for serum 
concentrations of L, which remained significant (p < 0.001, for all) using any of the standard 
corrections for violation of sphericity.  It is clear from the mean plots of Fig. 3., how these 
significant time/treatment interaction effects came about: serum concentrations of L increased 
with time in the A group, but remained virtually static in the P group. This time/treatment effect 
was significant from V2 (as expected and confirmed using paired t-test analysis between V1 and 
V2, p < 0.001). There was no statistically significant time or time/treatment interaction effect for 
serum concentrations of Z over the study period (p > 0.05, for all tests); however, there was a 
trend towards an increase in the A group.  
 
Visual Performance 
While the repeated measures ANOVA presented above is based on findings at all four study 
visits, it is apparent from the graphs (Fig.1 and Fig. 2) that the largest differences in MPOD 
between A and P subjects are between V1 and V4. The analysis of VP variables which follows 
is, therefore, confined to V1 and V4 only (controlling for between-subjects factors: treatment and 
smoking habits).  
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Using repeated measures ANOVA or a general linear model, as appropriate, we report a 
statistically significant time/treatment effect in only one measure of VP, namely “daily tasks 
comparative analysis” assessed subjectively (p = 0.03); whereas all other measures of VP were 
statistically non-significant (p > 0.05, for all) [see Table 2].  
 
Visual Performance differences: low MPOD versus high MPOD subjects 
We investigated whether subjects with high MPOD had significantly better VP scores than 
subjects with low MPOD following supplementation. We based this investigation, for the most 
part, on MPOD at 0.25º at V4. We used tertiles for V4 MPOD at 0.25º eccentricity to create low, 
medium and high MPOD groups, and then compared the low and high groups on a variety of VP 
measures assessed. The low group consisted of 31 subjects with V4 MPOD at or below 0.46 
optical density and the high MPOD group had 29 subjects with V4 MPOD at or above 0.69 
optical density [Fig. 4]. Table 3 presents results for VP measures which differ significantly 
between these low and high MPOD groups. Table 3 also presents the corresponding results for 
V1. It should be noted that differences in these VP measures at V1 were not, in general, 
statistically significant.  
 
Discussion 
COMPASS is a randomized placebo-controlled clinical trial of oral supplementation with a 
formulation containing the macular carotenoids (L and Z) and co-antioxidants versus placebo in 
young normal subjects The pre-specified hypothesis was that supplementation, and 
consequential MPOD augmentation, would result in improved visual performance and/or 
comfort in those randomized to the A arm when compared with the P arm, by 12 months.  
COMPASS was designed to investigate whether augmentation of MP results in 
enhancement of visual performance and/or experience, regardless of the mechanism(s) 
whereby any such improvements may be realized. The optical and neuroprotective hypotheses 
around MP, which have been discussed previously by Reading & Weale(Reading & Weale 
1974), later by Nussbaum et al.(Nussbaum, Pruett, & Delori 1981a) and are extended here, 
have generated interest amongst macular pigment scientists, evident in a recent 
review.(Loughman et al. 2010b) In brief, some authors have suggested that MP may be 
important for visual performance and/or experience by at least one of a number of mechanisms, 
including the reduction of the effects of chromatic aberration, light scatter, higher order 
aberrations, and plane polarization of light.(Loughman, Davison, Nolan, Akkali, & Beatty 
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2010b;Walls & Judd 1933) Importantly, however, and in theory at least, the macular carotenoids 
have the capacity to confer these optical advantages because of their light filtering and dichroic 
properties and because of their central location within the retina and crystalline lens.  
 An additional consideration in relation to any trial investigating the impact of MP 
augmentation on visual performance and experience is the potential beneficial effect of MP on 
neurophysiological health. For example, the majority of studies investigating the effects of MP 
augmentation in ocular disease, including AMD (summarized by Loughman et al.,)(Loughman, 
Davison, Nolan, Akkali, & Beatty 2010b), have reported a beneficial effect on vision, and such 
findings are probably attributable to the neuroprotective, as opposed to the optical, properties of 
these intracellular compounds. These studies have traditionally employed basic psychophysical 
outcome measures, including visual acuity and contrast sensitivity, and as such have not 
included stimuli likely to reveal improvements facilitated solely by image enhancement 
attributable to the optical properties of this pigment.  
The study formulation used in COMPASS, in addition to L and Z, contained the co-
antioxidants vitamin C, vitamin E, zinc and selenium. In contrast to the capacity to measure 
subjects’ retinal response to supplementation with the macular carotenoids (i.e. by measuring 
MP) it was not possible to assess, or quantify, subjects’ response to supplementation with the 
above named co-antioxidants. It is important to note that, as seen in the age-related eye 
disease study (AREDS),(Kassoff & The AREDS research group 2001) that these antioxidants 
may have contributed to any benefits reported in visual performance in the current study.  
Interestingly, several studies have reported, amongst normal subjects, findings which 
suggest that MP may play a key role in visual health through a complex interplay between the 
optical, neurological and physiological mechanisms underlying vision. These observations 
include (a) better critical flicker fusion frequency (CFF) in the presence of higher MPOD 
(Hammond & Wooten 2005), (b) associations between high MPOD and crystalline lens 
transparency and cataract formation(Brown et al. 1989;Chasan-Taber et al. 1999;Hammond, 
Wooten, & Snodderly 1997), (c) the presence of L and Z in substantial concentrations in the 
primary visual cortex(Craft et al. 2004) and (d) higher pattern electroretinogram (PERG) P50 
amplitudes and better dark adapted cone sensitivities in association with higher MPOD(Carboni 
et al. 2010) (Carboni et al., 2010 ARVO Abstract 1293 –A105).   
 The randomized design of COMPASS resulted in desirable baseline similarity between A 
and P groups on possible confounding variables, with the exception of smoking habits (which 
was controlled for throughout analysis, as appropriate).  Significant efforts were made to 
encourage compliance during the study, and based on the number of tablets returned, we 
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calculated that 95% of subjects averaged at least one tablet per day, with the average number 
of tablets consumed per day statistically comparable between the A and P groups (at around 
1.6 tablets per day).  
Consistent with the positive tablet compliance, on average, serum L concentrations 
increased significantly over the course of the study in the A group with no significant change 
observed in the P group. Indeed, despite the slight drop in mean serum L concentrations 
between V3 and V4 in the A group, L concentrations more than doubled in the A group over the 
course of the study. This finding is consistent with other and recent L interventional 
studies.(Bone & Landrum 2010;Trieschmann et al. 2007b) However, while average serum L 
concentrations significantly increased in the A group and remained stable in the P group, it is 
important to point out that 9 (23%) of the A group showed negative or zero change in serum L 
concentrations. This “non-response” to L supplementation in serum is consistent with an 
observation by Hammond et al. in 1997 who reported that one subject (out of 11 measured) 
demonstrated no significant change in serum concentrations of L following consumption of ~12 
mg of L per day over a 15 week study period (albeit L consumption in that study was achieved 
from diet [e.g. spinach and corn] and not from dietary supplements [as in the current study]).  To 
explain the high percentage of serum non-response in the current study, we propose the 
following possibilities: non-compliance with respect to consumption of the study tablet in these 
subjects: possible attenuation of the gastrointestinal absorption of supplemental L and Z if the 
subject fails to take the study tablet in the presence of synchronously ingested fat or oil 
(importantly, subjects were instructed to consume the daily dose of two tablets with a meal to 
facilitate the bioavailability of L from the tablet). Indeed, it has been shown that the amount of fat 
in a person’s diet significantly affects the absorption of L ester and its bioavailability, and given 
that the tablet used in the current study was a film coated tablet not containing oil, failure to 
consume the study formulation in the presence of fat and/or oil (i.e. with a meal) could 
significantly impact on the bioavailability of L (Roodenburg et al. 2000) Mean serum 
concentrations of Z also increased in the A group, but the increase was not statistically 
significant, probably due to the low concentration of this carotenoid in the study formulation (~1 
mg/day).  
Central MPOD increased significantly in the A group over the 12-month study period and 
remained stable in the P group. However, the observed increase in central MPOD in the A 
group only became apparent (significantly) at 12 months (whereas, as seen above, serum 
concentrations of L were significantly augmented in the A group at three months). This finding is 
consistent with previously published studies reporting slow uptake of L by the retina, (Bone et al. 
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2003;Johnson et al. 2000) and inconsistent with others.(Connolly, Beatty, Thurnham, 
Loughman, Howard, Stack, & Nolan 2010) However, it should be noted that the retinal uptake in 
our study was much slower than any of these previously published studies. For example, Bone 
et al. report that no significant change in MP was seen until after day 40 following 
supplementation with L and Z with up to 30 mg/day of each carotenoid and Johnson et al. report 
a significant increase in MP after 4 weeks of consuming 60 g/day spinach and 150 g/day corn. 
However, the reason(s) for the difference seen between studies may be due to any (or a 
combination of) the following factors: dose of L and Z consumed per day; type of L and Z in the 
supplement (e.g. free versus ester) matrix in which carotenoids are consumed (e.g. oil versus 
micro-encapsulated); whether consumed alone or in the presence of other antioxidants; poor 
serum response to the supplement; non-compliance to the study supplement. Further, and 
detailed, study on this interesting topic is merited. 
The average increase seen in the A group at 0.5º of retinal eccentricity (the standard 
and most commonly measured and reported MPOD eccentricity) over the 12-month study 
period was 0.11± 0.005 optical density, which is comparable to the findings of Trieschmann et 
al. who reported an average increase in MP of 0.10 ± 0.009 optical density where they 
measured MPOD by 2-wavelength autofluorescence.  Interestingly, Trieschmann et al. used the 
same study formulation (daily consumption of 12 mg of L provided as ester) over a 12-month 
study period as that used in the current study, but by delivering four tablets per day (each 
containing 3 mg of L ester), whereas the current study achieved a daily consumption of 12 mg 
of L ester by delivering two tablets per day.(Trieschmann et al. 2007a)  Unlike the findings 
reported by Trieschmann et al., we report that the biggest gain in MPOD in the A group did not, 
in general, occur in subjects with lowest baseline MPOD values. However, consistent with the 
data reported by Trieschmann et al., who reported that 20 (21%) of 92 subjects assessed were 
retinal non-responders (at 0.5 º), we found that eight (17%) of the A group at 0.25º and nine 
(20%) of the A group at 0.5º showed negative or zero change in MP at 12 months.  
In contrast with the MP measures discussed above, the VP measures assessed in the 
current study did not, in general, improve significantly over time in the A group. This would, 
superficially at least, seem to be at odds with the optical and visual health hypotheses of MP’s 
function.  Indeed, it is important to emphasise that, of all the VP measures assessed, and 
reported on, in COMPASS (48 variables in total; see Table 2) we report a statistically significant 
result for only one measure, namely “daily tasks comparative analysis”, assessed subjectively.   
It is possible, therefore, as data from the current study suggest, that supplementation with the 
macular carotenoids, and consequential MP augmentation, has no major impact on visual 
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performance and/or experience in young normal subjects (our primary research question and 
the main study hypothesis). This is, however, at odds with previous reports with respect to the 
impact of MPOD augmentation on glare disability.(Stringham & Hammond, Jr. 2005;Stringham 
& Hammond 2008). This discrepancy with earlier findings may be explained, at least partly, by 
two fundamental differences between the relevant studies. Firstly, COMPASS was designed to 
evaluate glare disability under conditions approximating normal environmental experience. As 
such, testing was conducted using natural pupils, which typically constrict under glare 
conditions, and therefore confer protection against the effects of glare. The Maxwellian view 
system employed in other studies does not allow normal pupillary response, so, while MP was 
shown to impact glare disability under these conditions, it is not clear whether the effect would 
have remained if a pupillary response had been allowed, which would have caused a variable 
reduction in retinal illuminance proportional to the magnitude of the pupillary response. 
Secondly, our findings can only be applied to the stimulus and glare intensity settings employed 
here, which, although informed by a detailed pilot study, are less comprehensive than the 
variable glare annulus intensity employed by Stringham & Hammond.  
Kvansakul et al.(Kvansakul, Rodriguez-Carmona, Edgar, Barker, Kopcke, Schalch, & 
Barbur 2006) conducted a study to evaluate the effect of MP supplementation on mesopic 
contrast acuity thresholds (CAT) in normal subjects.(Kvansakul, Rodriguez-Carmona, Edgar, 
Barker, Kopcke, Schalch, & Barbur 2006) They reported a significant and beneficial effect of MP 
supplementation on mesopic CAT that was not evident in their placebo group, their findings 
therefore appearing to be at odds with those of the current study, probably reflecting a number 
of differences between the two studies in terms of methodology and design [e.g. stimuli, 
illumination levels (1cdm-2 vs 3cdm-2), etc]. Also, the design by Kvansakul  et al. did not 
incorporate longitudinal evaluation of MPOD, which was measured only at the final visit 
(interestingly the CATs reported by Kvansakul showed no correlation with MPOD). Furthermore, 
contrast acuity thresholds were not measured at baseline, but only after six months of 
supplementation and then again at the final 12 month visit. One cannot, therefore, draw 
meaningful conclusions with respect to the relationship, if any, between their mesopic CAT 
findings and MPOD, as there is no record of change in MPOD over their study period. A final 
point relates to the sample sizes of the two studies, the investigation by Kvansakul et al. being 
based on a placebo group of only five subjects and three groups of subjects receiving 
supplementation (containing three, five and five subjects respectively) and is thus not 
comparable with the COMPASS trial, involving 121 subjects. 
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 There are however, a number of plausible explanations for the absence of any 
significant influence of MP augmentation on visual performance in our study. Firstly, it should be 
noted that the majority of study participants exhibited average to high central MPOD pre-
supplementation. Indeed, only a small number of subjects (~24%) were found to have central 
MPOD (at 0.5º eccentricity) less than 0.30 at baseline. Importantly, it has been suggested 
previously that MPOD levels greater than 0.30 might be superfluous to visual performance 
requirements,(Reading & Weale 1974) due to the non-linear nature of the effect of MP on vision. 
Furthermore, the increase in MPOD observed in the A group did not become apparent until the 
final 12 month visit, and was relatively modest with an average increase of 0.11 ± 0.005 optical 
density (at 0.5º eccentricity), and unlike the findings reported by Trieschmann et al, subjects (in 
the A group) in the current study with the lowest MP at baseline did not, in general, demonstrate 
the biggest increase in MPOD levels following supplementation with the study formulation. 
Indeed, even after 12-months of supplementation with 12 mg of L per day, over 15% of subjects 
in the A group retained central MPOD (at 0.5º eccentricity) values below 0.3 optical densit.  In 
other words, it is possible that the MP augmentation achieved in the current study was not 
sufficient (in an adequate number of subjects) to impact on visual performance, and that a 
greater increase in MPOD, particularly in the group with lowest baseline MPOD, might be 
required to elicit an improvement in visual performance. Also, as mentioned above, it is also 
likely that a significant number of subjects in the current study already had (at baseline) 
sufficient MP for optimal, measurable, and appreciable visual performance (i.e. 75% of subjects 
in the A group had baseline MP values  0.3 optical density) and therefore may explain, at least 
in part, the failure of the current study to demonstrate an improvement in VP following 
supplemental L.  
In addition, the nature of the tests employed for visual performance testing in COMPASS 
also merits consideration and discussion. The investigators strategically chose to use tests that 
were either typically available in the average consulting room (to ensure applicability of findings 
to clinical practice), or designed to replicate typical environmental conditions. As such, most of 
the tests did not contain substantial amounts of short wavelength light maximally absorbed by 
MP. The typical office or home environment (where the majority of us spend most of our time), 
does not have many short wave dominated light sources. Our results might, therefore, suggest 
that subjects’ MP levels pre supplementation were sufficient for optimal visual performance in 
this type of environment. Our results, therefore, cannot be extrapolated to short wave dominated 
visual scenes, such as against the background of a bright blue sky, which is difficult to replicate 
in an ecologically valid way. Importantly, the changing nature of internal and device lighting 
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systems, such as the increased use of LED systems, and xenon car headlights, are extending 
our exposure to short wave light sources, and may enhance the applicable relevance of MP for 
visual performance  
However, given that our study subjects showed an extensive range of MP values, we 
considered it meaningful to compare VP and comfort measures for subjects with high MP (upper 
tertile) versus subjects with low MP (lower tertile). We made these comparisons at baseline and 
also at V4. At V1, the subjects in the low MP group (for central MP at 0.25º) were below 0.42 
optical density, whereas subjects in the high MP group (for central MP at 0.25º) were above 
0.59 optical density. At V4, the corresponding figures for low and high groups were 0.46 and 
0.67 optical density.  Supplementation with L, therefore, appears to have widened the gap in MP 
between the lower and upper tertiles. Of interest, at V4 we report statistically significant 
differences in some important VP measures, between lower and upper MP tertile groups, which 
were not present at V1. 
 The most significant finding is that of a ~30% greater CS under high glare conditions in 
those with highest MPOD following supplementation. Interestingly, of all the tests employed in 
COMPASS, the glare source contained the most substantial amount of short wave light (white 
LEDs used to generate glare contain a single “blue” peak around 460nm). These results 
therefore would seem to corroborate previous findings which suggest a role for MP in the 
attenuation of glare disability,(Stringham & Hammond, Jr. 2007;Stringham & Hammond 
2008;Stringham, Fuld, & Wenzel 2004) and furthermore would seem to extend those findings to 
suggest that MP augmentation is beneficial for visual performance under glare conditions, even 
under the natural pupil conditions employed here. This finding and hypothesis is also supported 
by the results of the visual performance questionnaire. Subjects in the A group reported 
comparatively, and statistically significantly, better visual performance for daily visual tasks 
(including night driving against oncoming headlights). Furthermore, in the tertile analysis, those 
with the highest MP reported comparatively, and statistically significantly, better, capacity to 
deal with sudden changes in illumination (light/dark adaptation).  
In conclusion, we report that a significant increase in central MP following L 
supplementation does not, in general, impact on VP in young normal subjects, and our pre-
specified hypothesis that MP augmentation would result in improved VP and/or comfort by 12 
months, in those randomized to the A arm, remains unproven. However, subjects with high MP 
following L supplementation demonstrate visual benefits with respect to glare disability and 
mesopic CS.  Further study into MP and its relationship with VP is warranted to enhance our 
understanding of this pigment’s role. However, in order to investigate the impact of MP 
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augmentation on visual performance, the findings of our study suggest that we should direct our 
attention to a) subjects with low baseline central MP levels, b) subjects with suboptimal visual 
performance and c) subjects with symptoms of glare disability.   
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Table 1:  Demographic, lifestyle, vision, and macular pigment data at baseline 
Characteristic All 
*n = 121 
A 
n = 61 
P 
n = 60 
sig. 
Age 29 ± 7 29 ± 7 29 ± 6 0.864 
Body mass index 26 ± 4 26 ± 4 25 ± 3 0.736 
Best corrected visual acuity 113 ± 3 113 ± 3 112 ± 3 0.747 
Macular pigment optical density 
    
0.25º 0.5 ± 0.19 0.49 ± 0.19 0.51 ± 0.20 0.458 
0.5º 0.4 ± 0.17 0.39 ± 0.16 0.41 ± 0.18 0.425 
1º 0.22 ± 0.13 0.20 ± 0.12 0.22 ± 0.15 0.433 
1.75º 0.10 ± 0.11 0.09 ± 0.10 0.10 ± 0.11 0.376 
3º 
Dietary carotenoids (mg/day) 
Lutein  
Zeaxanthin 
Serum carotenoids (µmol/L) 
Lutein 
Zeaxanthin 
0.10 ± 0.10 
 
1.26 ± 0.95 
0.21 ± 0.12 
 
0.60 ± 0.32 
0.36 ± 0.17 
0.08 ± 0.08 
 
1.16 ± 0.96 
0.19 ± 0.10 
 
0.57 ± 0.27 
0.36 ± 0.15 
0.12 ± 0.12 
 
1.36 ± 0.94 
0.23 ± 0.14 
 
0.62 ± 0.36 
0.37 ± 0.18 
0.058 
 
0.253 
0.074 
 
0.399 
0.623 
Sex 
    
Male 69 34 35  
Female 52 27 25 0.773 
Smoking habits† 
    
Never smoked 73 42 31  
Ex-smoker  21 11 10  
Current smoker  27 8 19 0.046 
 
 *n = sample size; **sig. = probability significance value; †smoking habits: ex-smoker = smoked  100 
cigarettes in lifetime but none in last 12 months; current smoker = smoked  100 cigarettes in lifetime and 
at least 1 cigarette per week in last 12 months; A = active group and P = Placebo group                    
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Table 2. Repeated measures assessment of all VP measures in COMPASS 
Visual Performance Measure Sub-Measure/Device p-value  
 
  
Glare Disability Medium Glare (Optec)  
 1.5 cpd 0.58 
 3.0 cpd 0.94 
 6.0 cpd 0.65 
 12.0 cpd 0.96 
 18.0 cpd 0.49 
 
  
Glare Disability High Glare (Optec)  
 1.5 cpd 0.19 
 3.0 cpd 0.99 
 6.0 cpd 0.89 
 12.0 cpd 0.41 
 18.0 cpd 0.86 
 
  
Glare Questionnaire Glare comparative analysis  0.32 
 Glare Change Analysis 0.88 
 Glare situational analysis 0.74 
 Glare subject satisfaction score 0.51 
 
  
Visual Acuity BCVA (Thomson Chart) 0.16 
 
  
Visual Acuity Questionnaire Acuity comparative analysis 0.08 
 Acuity Change Analysis 0.15 
 Acuity situational analysis 0.14 
 Acuity subject satisfaction score 0.59 
 
  
Daily Tasks Questionnaire Daily Tasks comparative analysis 0.03* 
 Daily Tasks Change Analysis 0.21 
 Daily Tasks situational analysis 0.27 
 Daily Tasks subject satisfaction score 0.41 
 
  
Light-Dark Adaptation Questionnaire Light-Dark comparative analysis 0.35 
 Light-Dark Change Analysis 0.15 
 Light-Dark situational analysis 0.75 
 Light-Dark subject satisfaction score 0.56 
 
  
Mesopic Contrast Sensitivity  F.A.C.T. (Optec)  
 1.5 cpd 0.72 
 3.0 cpd 0.77 
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 6.0 cpd 0.84 
 12.0 cpd 0.66 
 18.0 cpd 0.5 
 
  
Mesopic Contrast Sensitivity Metropsis  
 1.0 cpd 0.54 
 4.1 cpd 0.79 
 7.5 cpd 0.82 
 11.8 cpd 0.18 
 20.7 cpd 0.08 
 
  
Photopic Contrast Sensitivity Metropsis  
 1.0 cpd 0.95 
 4.1 cpd 0.42 
 7.5 cpd 0.31 
 11.8 cpd 0.19 
 20.7 cpd 0.87 
 
  
Critical Flicker Fusion Frequency Densitometer 0.3 
 
  
Foveal Sensitivity Humphrey Perimeter 0.93 
VP = visual performance; **sig. = probability significance value 
Four VP variables in this study were recorded as percentage change of V4 score compared to V1 score. 
Repeated measures analysis would not have been appropriate for these, and instead they were analysed 
using a general linear model with V4 percentage change as the dependent variable and fixed between-
subjects factors Treatment and Smoking as explanatory variables.  
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Table 3: Comparing visual performance measures between low and high macular pigment 
optical density groups at visit 4 and visit 1 
        Visit 4         Visit 1 
	
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* MP Group= macular pigment optical density group tertile for 0.25º eccentricity: high = top tertile, low = 
bottom tertile; ''Mesopic CS at 1.5 cpd under high glare = night-time contrast sensitivity at low spatial 
frequencies assessed under high glare conditions; † Light/Dark adaptation comparative analysis =  self 
reported visual performance under changing light conditions compared to friends/family/peers;  = 
Mesopic contrast sensitivity at 20.7 cpd = night time contrast sensitivity measured at high spatial 
frequencies. 
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Figure 1: Change in MPOD at each eccentricity measured, over the 12-month study period, 
following supplementation in both the active and placebo groups 
Repeated measure results for MPOD over the four study visits and analyzing visit*treatment interaction at 
eccentricities 0.25 º, 0.5 º, 1.0 º, 1.75 º and 3 º. The p-values reported are for the Greenhouse-Geisser 
correction for violation of sphericity and are as follows: MPOD 0.25 = p < 0.001; MPOD 0.5 = p < 0.001; 
MPOD 1.0 = 0.001; MPOD 1.75 = 0.585; MPOD 3.0 = 0.103. Subjects were assessed at baseline, three, 
six, and 12 months (V1, V2, V3 and V4, respectively) 
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Figure 2: Change in MPOD at 0.25º eccentricity for 20 subjects from each of active and 
placebo groups 
 
 
* MP 0.25° = macular pigment optical density at 0.25° degrees of eccentricity 
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Figure 3: Change in serum concentrations of lutein over the 12-month study period, following 
supplementation in both the active and placebo groups 
 
 
 
 
 
 
 
 
 
 
 
Mean (±SD) serum concentrations of lutein were quantified by high-performance liquid chromatography at 
baseline, three, six, and 12 months (V1, V2, V3 and V4, respectively) 
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Figure 4: Boxplots of V4 MPOD at 0.25º showing range of values for each tertile 
group
 
* MPOD 0.25° at visit 4 = macular pigment optical density at 0.25° degrees of eccentricity at visit four (12-
months) presented for each tertile boxplot. Low, medium and high boxplots represent low tertile group, 
medium tertile group and high tertile groups with respect to MPOD measured at 0.25° degrees of 
eccentricity. Black dots represent extreme values (outliers).  
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